Discover how a configurable treatment value model empowers pharmaceutical companies, healthcare professionals, and patients in emerging therapeutic markets—enhancing drug launch strategies, treatment access, and clinical decision-making with real-world data and cost transparency.| Evaluate
All-in-one pharmaceutical forecasting platform. FC365 simplifies complex forecasting via a centralised, shared cloud-based interface.| Evaluate
Pharma forecasting training, providing insight into sales, oncology and epi-based techniques, delivered by leading experts in the industry.| Evaluate
With Evaluate Data Feeds, integrate forecast, trial and key event data into your systems and workflows, saving time and accelerating strategic decision making| Evaluate
Evaluate's pharmaceutical consulting and analytics team provide expert solutions for your unique scientific, clinical, and commercial challenges, enhancing your strategy.| Evaluate
Biomedtracker provides a holistic view of the drug development landscape with real-time tracking of events, catalysts and deals.| Evaluate
Find out how Evaluate can help you - pharma & biotech, financial services, management consultancies, medtech & service providers to the pharma industry| Evaluate
There are many challenges that biopharma forecasters face but perhaps one of the greatest is asking people to change their behavior. No matter how many fancy forecasting tools and solutions you may have, people know what they like and one thing they like is Excel. In this video, I talk about why there is still […] The post What’s the role of Excel in a Forecaster’s Software Toolkit? appeared first on Evaluate.| Evaluate
The obesity sector has witnessed robust GLP-1 deal making with pharma companies showing unprecedented appetite for strategic pharma deals.| Evaluate
Read how a biotech VC firm sharpened investment strategy with data-driven insights, rare disease focus, and lifecycle support| Evaluate
Discover how pharma forecasting teams can navigate Loss of Exclusivity (LoE) with precision. Learn strategies to manage asset saturation, biosimilar impact, and regional planning in today’s competitive pipeline landscape.| Evaluate
Explore the market catalysts driven by 23 drugs, devices, diagnostics, and deals anticipated in Q2 2025.| Evaluate
Explore Evaluate’s Q2 2025 biopharma report for the latest insights on M&A, IPOs, venture funding, and China’s rising influence. Essential reading for pharma, biotech, and pharma investors.| Evaluate
BIO International 2025 highlights, including trends in biotech investment, M&A activity, licensing, and the role of China in global biopharma. Download now for expert commentary, market statistics, and strategic guidance.| Evaluate
“Nuclear winter” and “extinction event” were two of the less-than-positive terms used during last month’s BIO International convention to describe the biotech investment landscape..| Evaluate
Explore advanced oncology forecasting strategies in our latest eBook—covering treatment pathways, biomarker segmentation, PD-1 therapies, and more. Download now| Evaluate
Every year, I am hugely fortunate to work with our team of experts to create the Evaluate World Preview report. Now in its 18th year, the World Preview offers a data-rich look at the future of the pharmaceutical industry. It’s full of forecast data that help to paint a picture of the shifting sands of […] The post Three Things we Learned in our World Preview 2025 Webinar appeared first on Evaluate.| Evaluate
The World Preview webinar will include many data highlights from the report as well as discussion of the big themes in the market.| Evaluate
Discover key insights from Evaluate’s World Preview 2025 infographic, including GLP-1 growth, China’s biotech ascent, and looming patent expiries. Download now.| Evaluate
Master your pharma forecasting with epidemiology, patient-flow, and sales-based methodologies. Download the eBook for expert insights and best practices.| Evaluate
Discover how a clinical-stage biotech partnered with J+D Forecasting to transform its oncology forecasting—accelerating Phase III launch readiness, building internal capability, and enabling strategic pipeline decisions with Onco+.| Evaluate
Make the most of the ASCO 2025 Annual Meeting with our expertly curated Weekend Planner, your essential tool for navigating the most commercially relevant presentations and data releases from oncology’s biggest event.| Evaluate
Discover 5 expert tips to make your pharmaceutical forecasts more interactive, insightful, and tailored to stakeholders - download the free infographic now.| Evaluate
This one-page guide highlights five expert tips tohelp you navigate the unique challenges of oncology forecasting withgreater confidence.| Evaluate
Pharma market growth forecasts and drug sales to 2030 reflect solid underlying demand. But much is changing across the biopharma landscape.| Evaluate
Drug sales to hit $1.75T by 2030, led by GLP-1s and China’s biotech rise amid global pharma shifts.| Evaluate
Key announcements and data from the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), with accompanying analyses.| Evaluate
Master your pharma forecasting with epidemiology, patient-flow, and sales-based methodologies. Download the eBook for expert insights and best practices.| Evaluate
Recently, the J+D Forecasting team welcomed a diverse group of professionals to Boston for our two-day Fundamentals of Forecasting multi-client workshop, run in collaboration with Evaluate. From emerging clinical-stage biotechs to global Top 10 pharma companies, delegates gathered to deepen their knowledge, share experiences, and engage in peer-to-peer learning in a relaxed, collaborative environment. The […] The post Inside the Fundamentals of Forecasting: Highlights from Our Boston Worksh...| Evaluate
Key considerations for creating more accurate patient-based product forecasts.| Evaluate
Evaluate’s custom analytics team help you to address unique commercial challenges. We answer key asset, portfolio, and corporate strategy-related questions, powered by the combined resources of Norstella.| Evaluate
The board at Verona Pharma was taking the steps necessary to take its chronic obstructive pulmonary disorder (COPD) drug to market years ahead of its launch in 2024. This long term view was one of the details shared by Verona’s Chief Commercial Officer, Chris Martin during our recent webinar “Going Solo: What’s Driving the Biotech […] The post Three Things we Learned in our Biotech Commercialization Webinar appeared first on Evaluate.| Evaluate
“Think twice, and twice more, before launching your own drug. It is unimaginably difficult and complex”. Those were the words of a biotech CEO I interviewed more than a decade ago. The advice remains sound. Yet today there are tailwinds encouraging more biotechs to take their prized assets all the way to market. (And let’s […] The post A Blueprint for Biotech Commercialization? appeared first on Evaluate.| Evaluate
When it comes to forecasting sales in the pharmaceutical industry, several time series algorithms are commonly used to analyze historical data and project trends into the future. These can be classified into three main types: Automated Smoothing First is the automated smoothing algorithm. This includes techniques such as growth rates and linear regression. Smoothing algorithms […] The post Choosing the most Appropriate Time Series Algorithm for Accurate Pharmaceutical Sales Forecasts appear...| Evaluate
Discover 3 key insights from our webinar on first to market advantage in the pharma industry. Learn how these findings can impact your portfolio strategy.| Evaluate
Discover the top 15 market catalysts in Q2 2025 across drugs, devices, diagnostics, and deals.| Evaluate
Biotechs sponsor a growing share of new drugs & many are commercializing their products too. What are the steps to successful biotech commercialization?| Evaluate
Insmed CEO Will Lewis talked to Evaluate about the biotech’s orphan drug strategy, why it is still committed to rare diseases, and how orphan drug benefits might be better targeted.| Evaluate
What did 2024’s biggest biopharma deals reveal about the state of the industry? Find out more in our Deal-making Roundup.| Evaluate
For Portfolio Strategy teams in pharma companies, there is a constant juggling act to ensure that the right therapies are being prioritized for the right indications. This requires a clear understanding of the potential market size, payer perspectives and competitive environment. With the right data and insight, you can plan your go-to-market approach – and […] The post Should Pharma Companies Really Race to be First to Market? appeared first on Evaluate.| Evaluate
In our webinar about long-range planning processes in pharma we looked at the foundational pieces you need to achieve accurate forecasts| Evaluate
In this session we’ll dive deeper into addressing pain points and equipping attendees with practical solutions like standardized forecasting, automation, and cloud-based tools.| Evaluate
Competitive Intelligence teams occupy quite a unique place in a biopharma organization. They collaborate with a really wide range of stakeholders – sales, regulatory, forecasting and many more. This gives CI professionals insight into countless strategic initiatives across the company. But it also means trying to support a lot of different, sometimes almost contradictory needs. […] The post The High-Stakes Landscape for Competitive Intelligence appeared first on Evaluate.| Evaluate
Having good forecast models is critical for effective and efficient decision-making. This will deliver accurate and reliable insights to help support business objectives and drive brand or company growth, highlight risk, and quantify opportunity. This article explores the key ingredients needed for developing good pharmaceutical forecast models. It’s widely accepted that there is no such […] The post What makes a good (and bad) pharmaceutical forecast model appeared first on Evaluate.| Evaluate
Join our webinar, Mastering Long-Range Planning to help you refine your forecasting approach, improve collaboration & drive decision-making.| Evaluate
The lines between orphan drugs and mainstream prescription drugs are blurring. In this infographic, we look at the top orphan drugs and the wider market for drugs for rare diseases.| Evaluate
Orphan drugs for rare diseases are set to make up one fifth of the of all prescription drug sales by 2030. This report investigates the orphan drug landscape out to 2030.| Evaluate
Biotech FDA approvals accounted for two thirds of the 2024 total – a big shift from 2023. We investigate the drivers and challenges for small players going it alone.| Evaluate
2024 Review of Pharma - Analysis of the state of dealmaking, investment & stock price performance of the biopharma sector in 2024| Evaluate
No element of pharmaceutical forecasting is easy but there’s a particular challenge in long-range planning. The range of components involved results in a greater degree of complexity which can allow inaccuracies to creep in very easily. We covered some of the key challenges in a recent webinar, The Forecaster’s Guide to Long-Range Planning, which you […] The post How can you Improve Efficiencies in your Long-Range Planning? appeared first on Evaluate.| Evaluate
Our recent orphan drugs webinar provided a wealth of insights into the current state and future of the orphan drug market. It was based on our annual report (which is available here) and if you missed it, I recommend taking the time to watch the on-demand version. Our panel included the report’s author, Melanie Senior […] The post Three Things We Learned in Our Orphan Drugs Webinar appeared first on Evaluate.| Evaluate
Evaluate produces some really valuable reports, webinars and articles that provide insight about the pharma market. Find the latest here.| Evaluate
If you follow Evaluate’s regular white papers and blogs, you may be familiar with our annual report that investigates the state of the orphan drug market. I’ve been involved in analyzing that data for the past three years, and have just finished the process for this year’s report which will be published soon. One of […] The post Is it Time to Rethink Orphan Drugs? appeared first on Evaluate.| Evaluate
Enhance your forecasting expertise with J+D's training programs. Boost confidence and skills through self-assessment, tailored courses, and real-world applications.| Evaluate
Join us for an insightful session, as we tackle the common challenges associated throughout the Long-Range Planning cycle.| Evaluate
In our long-range planning in pharma webinar, we looked at the challenges and best practices to ensure successful 5-10 year forecasts.| Evaluate
Join our webinar, The Forecaster’s Guide to Long-Range Planning, to uncover key challenges, explore solutions, and gain practical strategies for success.| Evaluate
In our 2025 Preview webinar our panel discussed the evolution of obesity drugs, the role of China in pharma dealmaking & biotech commercialisation.| Evaluate
Discover our comprehensive thought leadership library featuring the latest data-driven reports, captivating infographics, and insightful articles addressing key industry issues, niche topics, and everything in between.| Evaluate
What does 2025 have in store for pharma forecasting teams? We explore the evolving role of forecasting teams in the pharmaceutical industry.| Evaluate
How can forecasters use analogue forecasting to accurately predict a new drug’s impact on the treatment landscape?| Evaluate
Once again, the pharma industry starts a new year with hopes of a recovery. Will 2025 finally see a return of IPOs? Of mega-mergers? Of huge rounds of investment? Perhaps, but more likely this year will simply be a few steps in the right direction. There is still a great deal of uncertainty, particularly around […] The post What Will 2025 Hold for Pharma? appeared first on Evaluate.| Evaluate
Our Voice of the Customer lead, Magda Lis-Podjaska, shares her views on biopharma, CDMO and challenges for biotechs.| Evaluate
Explore our infographic on forecasting in pharmaceutical product management, highlighting key stakeholder considerations throughout the product lifecycle.| Evaluate
.Prepare for the patent cliff's impact on sales. This expert report from J+D Forecasting explores market shifts and forecasting strategies.| Evaluate
The oldest hub-and-spokes pharma companies are over 10 years old – has the portfolio biotech model been validated?| Evaluate
The term CDMO has become ubiquitous in the pharmaceutical industry over the past decade but does it represents a paradigm change in how drugs are developed and manufactured?| Evaluate
Evaluate’s latest report features 2025 pharma forecasts for top-selling drugs, biggest companies and potential novel drug approvals for the year ahead.| Evaluate
Your at-a-glance snapshot of Evaluate’s 2025 pharma forecasts of top drugs, companies and potential drug launches.| Evaluate
Obesity. The Inflation Reduction Act. Orphan Drugs. CDMOs. Successful forecasting techniques. We’ve covered all this and more in our biopharma reports, webinars and analysis throughout 2024. As I’ve had the pleasure of working with our experts to create all this content, I thought year-end was a splendid opportunity to share the most-read pieces of the […] The post Biopharma Reading List: The Evaluate Top 10 of 2024 appeared first on Evaluate.| Evaluate
The relationship between epidemiology forecasting and data sources is a complex one. Generating accurate forecasts relies heavily on data, and factors such as real-world data and artificial intelligence (AI) have an increasing impact. Factors affecting forecast quality and accuracy There are a few factors that contribute to the accuracy of epidemiological forecasts. Firstly, the […] The post Epidemiology forecasting and the impact of data sources on accuracy appeared first on Evaluate.| Evaluate
Picture the scene. You’ve got a new, hugely promising new drug in the pipeline and all the clinical signs are looking good. Which means you have to start focusing on your launch strategy to ensure commercial success. You need to refine your list of potential opportunities and threats, and develop forecasts that will ensure the […] The post Three Things we Learned in our Launch Excellence Webinar appeared first on Evaluate.| Evaluate
One of the great things about working in the pharma industry is the opportunity to listen to very clever people talking about fascinating topics and the latest trends in the market. Events like BIO-Europe are brilliant for this, and there is always plenty to unpack after the panels, keynotes and fireside chats have ended. Our […] The post Three Things we Learned in our “Taking the Pharma Industry Pulse” Webinar appeared first on Evaluate.| Evaluate
At the recent CPHI exhibition in a very wet Milan, you couldn’t move for booths expounding on the capabilities of the world’s manufacturing, services, packaging and ingredients players. Some of these companies formerly considered themselves to be Contract Research Organisations (CROs) or CMOs (Contract Manufacturing Organisations) but now proudly display the letters CDMO (Contract Development […] The post CDMOs: A Paradigm Change for Pharma? appeared first on Evaluate.| Evaluate
Launching a first-in-class drug is high on the wish list of most pharma companies, but achieving that goal is not without its challenges. While patient demand for innovative therapies will always be high, modelling their impact on the treatment landscape is an uncertain business and the stakes are too high to rely on little more […] The post Analogue forecasting: the power of the past to predict the future appeared first on Evaluate.| Evaluate
Penny Wills joined the Evaluate team through its acquisition of J+D Forecasting at the start of 2024. As a seasoned forecasting implementation expert, Penny’s role encompasses working closely with clients to understand their requirements for their forecasting models and ensuring successful delivery by working with stakeholders across the team. I grabbed some time with Penny […] The post Meet the Evaluate Team: Penny Wills appeared first on Evaluate.| Evaluate
BIO-Europe took place last week in Stockholm. It’s one of the last big biopharma events of the year and a great time to take stock of where the industry stands as the new year approaches. I was at the convention, taking part in a fireside chat to discuss global innovation trends. Also featuring on the […] The post Join the Discussion: Dealmaking, Innovation and Geopolitics in Pharma appeared first on Evaluate.| Evaluate
Pharma shifts to predictable trends, focusing on major drugs for big diseases. Evaluate’s 2030 forecast explores obesity and new tech.| Evaluate
Pharma M&A and IPOs started strong in 2024 but saw significant drops in Q2, with fewer deals and only three companies going public.| Evaluate
Discover key strategies for forecasting rare diseases, affecting 300M+ people globally. Learn from case studies and epidemiological models in our guide.| Evaluate
Explore Evaluate's analysis of 200 top-selling drugs to uncover what makes billion-dollar blockbusters. Get the Billion Dollar Blueprint infographic now.| Evaluate
Find out how Evaluate can help you - pharma & biotech, financial services, management consultancies, medtech & service providers to the pharma industry.| Evaluate
Volume is up but value is down. That’s the headline of the dealmaking scene for the first half of 2024. There’s not been a mega-merger in the vein of 2023’s Pfizer/Seagen deal, though the Novo/Catalent deal aimed at boosting supplies of the semaglutide products Ozempic and Wegovy is certainly notable. Even so, the 18% increase […] The post 2024 Dealmaking: What’s the Score? appeared first on Evaluate.| Evaluate
If you missed our recent webinar, AI and ML in Pharma: Redefining the Forecasting Landscape, then I hope it’s because you were on a lovely vacation somewhere. Now that you’re back, though, you’ll be delighted to know that it’s available on demand so you can catch up at your leisure. Our panel, which included Daniel […] The post In Case You Missed It: Three Things we Learned in our AI Forecasting Webinar appeared first on Evaluate.| Evaluate
You may have read the new report we recently published on the orphan drug market. Rare diseases and their therapies are a huge topic to cover so inevitably, we couldn’t cover everything in the report. However, that’s what webinars are for! I’m delighted to be taking part in Evaluate’s upcoming webinar which will explore the […] The post Orphans are Getting Strategic appeared first on Evaluate.| Evaluate
2024 has the potential to be a year full of partnering opportunities, driven by the much-discussed patent cliff as some of the biggest-selling drugs in history are set to lose exclusivity by 2028. Perhaps as much as 6% of the nearly $1.6 trillion overall drug market might be at risk and while this isn’t Big […] The post What’s the Deal? Navigating the Complex World of Pharma Business Development appeared first on Evaluate.| Evaluate
If you missed the recent news, Evaluate recently acquired J+D Forecasting, a provider of brilliant forecasting solutions to pharma and biotech companies. Andrew Ward has been with the J+D team for almost 10 years as Head of Implementation team, ensuring that the team is able to meet the ever-evolving needs of their customers. I grabbed […] The post Meet the Team: Andrew Ward appeared first on Evaluate.| Evaluate
Hot-off-the-press, Evaluate has just released its latest annual deep dive into the world of orphan drugs and rare diseases. I had the opportunity to preview the content and make the case for why it is essential biopharma reading below. And while I have your attention, you can grab your complimentary copy of Orphan Drug Report […] The post Orphan Drug Report 2024: Slowdown a Sign of Success appeared first on Evaluate.| Evaluate
The US Healthcare system is a vast, unwieldy beast that requires significant navigation by any company in the healthcare space. Whether you’re a Big Pharma, a small biotech or an innovative digital health developer, access to this market (and its payers) is likely to be make or break for your business. This, in a nutshell, […] The post US Health Systems: A Driving Force for Digital Health appeared first on Evaluate.| Evaluate
Dealmaking is a hallmark of the pharma industry. Whether to access innovative therapies, expand into new areas or fill a gap left from a failure in the clinic, pipelines need regular topping up to ensure companies can deliver long-term growth in the face of new competition, and loss of exclusivity. At Evaluate, we work closely […] The post Next Generation Dealmaking with Evaluate and Inpart appeared first on Evaluate.| Evaluate
Markella is part of Evaluate’s competitive intelligence (CI) consulting practice, where she works on a wide range of projects to support CI teams in pharma companies to ensure they stay on top of the latest developments and are able to deliver timely insights to their stakeholders. I caught up with Markella to learn about what […] The post Meet the Evaluate Team: Markella Kordoyanni appeared first on Evaluate.| Evaluate
The number of cell and gene therapy (C>)-based treatments in development has increased significantly over the last two decades and can be expected to continue, driven by the modality-specific market potential and the breadth of applicability across indications. For competitive intelligence teams tasked with staying on top of this complex and dynamic market, there is […] The post Competitive Intelligence Insights: Cell & Gene Therapy appeared first on Evaluate.| Evaluate
Our focus was on the 2024 Preview, our annual report that looks at the top drugs, companies, potential launches and much more for the year ahead. In the webinar, our team talked through some of the highlights and discussed some of the stories behind the data, with a view to what it means for pharma […] The post In Case You Missed It: Three Things We Learned in Our 2024 Preview Webinar appeared first on Evaluate.| Evaluate
Fortunately, the annual Preview report that we publish at Evaluate is based on our consensus forecasting data. While that doesn’t guarantee accuracy – in the current market, guarantees are hard to come by – it does mean that the insight we share is based on some pretty solid data. The 2024 Preview report was published […] The post Sneak Peek at Our 2024 Preview Webinar appeared first on Evaluate.| Evaluate
What’s in your competitor’s pipeline? How are their trials progressing? Who is on the cusp of a merger that will increase their funding and how will this impact your business? Continuous monitoring of the market landscape is the bread and butter of a CI professional and you can’t afford to miss anything that may impact […] The post Competitive Intelligence and the Quest for the Single Source of Truth appeared first on Evaluate.| Evaluate
Buzzwords in the life sciences industry – there are many: Artificial Intelligence (AI), Gen AI, Machine Learning (ML), digital health, and real-world data (RWD)/real world evidence (RWE). All are vast, complex areas with notable potential to impact our clients and the industry overall – across the continuum of the product lifecycle, spanning clinical and commercial […] The post Knowledge and Insights: The Power of Real-World Data appeared first on Evaluate.| Evaluate
After a year in which investor sentiment went from bad to worse, 2024 has started on a more positive note. Last week’s JP Morgan conference saw a flurry of partnership and acquisition announcements, building on the last couple of weeks of December which saw 2023’s deal making end with a bang. If the end is […] The post 2024 Preview: Are We There Yet? appeared first on Evaluate.| Evaluate
If you missed it, the recording is available here. If you’re short on time, here are three of the key points that I took away from the session. Our speakers included Amanda Micklus from the Norstella consulting team, and Vince Spurr, one of our CDMO experts. Perhaps more importantly, we were joined by Matt Hewitt […] The post In Case You Missed It: Three Things We Learned in Our CDMO Webinar appeared first on Evaluate.| Evaluate
There are two inflection points where a pharma or biotech company looks to a CDMO. In one instance, it’s a technology transfer to create regional or incremental capacity, helping reduce the risk of a single-source manufacturing process. While this isn’t risk-free, it’s relatively straightforward. In recent years, though, we’ve seen an increase in companies seeking […] The post In Sickness and in Health: The CDMO/Pharma Relationship appeared first on Evaluate.| Evaluate
There’s far too much to share in one blog post, but there were three areas that I wanted to summarise as I think they’re a good indicator of the current state of the biopharma market and give us an insight into what we can expect from pharma and biotech in 2024. 1. Dealmaking Increasing competition […] The post Themes from BIO Europe appeared first on Evaluate.| Evaluate
